不适合移植的大 B 细胞淋巴瘤二线使用 axicabtagene ciloleucel：ALYCANTE 最终分析
Second-line axicabtagene ciloleucel in large B-cell lymphoma ineligible for transplantation: ALYCANTE final analysis.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
首次完全缓解后 upfront 自体造血干细胞移植改善了晚期结外 NKT 细胞淋巴瘤的预后：一项中国多中心真实世界研究
英文原题：Up-front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra-nodal NKT cell lymphoma: A multicenter real-world study in China.
查看英文原题
Up-front autologous hematopoietic stem cell transplantation after first complete remission improved prognosis of advanced extra-nodal NKT cell lymphoma: A multicenter real-world study in China.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
前期 ASCT 可改善首次完全缓解的晚期 ENKTL 患者的生存，但需前瞻性临床试验证实。
研究思路结论见上方概要
目的
晚期结外NK/T细胞淋巴瘤（ENKTL）具有高度侵袭性，缺乏有效治疗手段，预后较差。本研究旨在探讨自体造血干细胞移植（ASCT）在CR1期的有效性和安全性。
方法
2006年1月至2021年12月期间，来自中国四家医院的121例晚期ENKTL患者中，有40例达到首次完全缓解（CR1）并接受至少4个周期化疗的患者被纳入分析。20例患者接受ASCT作为前期巩固治疗（A组），20例患者仅接受化疗（B组）。收集了临床特征、治疗及随访信息。
结果
中位随访27个月（范围4-188个月），A组2年总生存期（OS）为61%（95% CI 37%-85%），优于B组的26%（95% CI 2%-50%），p = .018。A组2年无进展生存期（PFS）为56%（95% CI 32%-80%），B组为26%（95% CI 2%-50%），p = .026。III-IV级血液学毒性是最常见的不良事件。两组均未观察到治疗相关死亡。
展开英文摘要原文
OBJECTIVES
The advanced extra-nodal NK/T-cell lymphoma (ENKTL) is highly aggressive and lacks effective treatment with a poor prognosis. This study aimed to investigate the effectiveness and safety of autologous hematopoietic stem cell transplantation (ASCT) in CR1.
METHODS
Forty of 121 patients with advanced ENKTL from four Chinese hospitals between January 2006 to December 2021 who achieved first complete remission (CR1) and received at least 4 cycles chemotherapy, were enrolled for analysis. Twenty patients received ASCT as up-front consolidation therapy (Group A), and 20 patients only received chemotherapy (Group B). Clinical features, treatment and follow-up information were collected.
RESULTS
With a median follow-up of 27 months (range, 4-188 months), the 2-year overall survival (OS) in Group A, 61% (95% CI 37%-85%), was better than that in Group B, 26% (95% CI 2%-50%), p = .018. The 2-year progression-free survival (PFS) was 56% (95% CI 32%-80%) in Group A, 26% (95% CI 2%-50%) in Group B, p = .026. III-IV grade hematological toxicity was the most common adverse event. No treatment-related deaths were observed in both groups.
CONCLUSION
Up-front ASCT could improve survival of advanced ENKTL patients in first complete remission, but need be confirmed by a prospective clinical trial.
论文信息
- 作者
- Gao H、Lin N、Gu Z、Zhao S、Wang X、Yuan S、Song Y、Zhu J
- 单位
- Senior Department of Hematology, The Fifth Medical Center of PLA General Hospital, Beijing, China.China
- 文献类型
- 多中心研究
- 期刊
- European journal of haematology2023 Jun
- 原文标识
- PubMed 36825748 · DOI 10.1111/ejh.13950